Cronos Group Reports Q3 2026 Financial Results

TORONTO – Cronos Group Inc. reported record net revenue of $63.5 million, up 75% from a year earlier and 73% on an organic, constant-currency basis. Gross profit rose 76% to $32.3 million, a 50.9% margin. Adjusted EBITDA reached $17.1 million, compared with $5.7 million a year ago.

Net income fell 37% to $17.8 million. The company pointed to lower other income, higher operating expenses and an income tax provision, compared with a benefit in 2025. Currency explains part of the gap. Last year’s quarter included a $19.8 million foreign exchange gain, while this quarter posted a $0.2 million loss. Operating income improved to $9 million from a $0.5 million loss, even with operating expenses up $4.4 million to $23.3 million on higher sales, marketing and administrative costs.

The Canadian market generated $35.1 million in net revenue, up 52%. Israel contributed $15.1 million, up 33% (19% at constant currency), its eleventh straight record. Other international markets brought in $13.2 million, up 614%, led by Germany. Cronos said Spinach® retail sales in Canada rose 41%, while national retail sales grew 1%. Sales in Israel and Germany carry no excise taxes, which helped margins. Excise taxes totaled $20.5 million on $83.9 million in sales before those taxes.

Cronos held $840.6 million in cash, restricted cash, short-term investments and interest-bearing deposits at quarter-end. Cash and equivalents alone fell to $411.2 million as the company shifted funds into short-term investments and deposits. Operating cash flow for the first nine months reached $69.2 million, up from $14 million. The company repurchased 3.2 million shares for $9.4 million in the quarter, and shares outstanding stood at 367.5 million, down from 381.6 million at the end of 2025.

In October, Cronos closed its purchase of Dutch grower CanAdelaar, securing the undisputed market-share leader inside the Dutch Wietexperiment – a government-designed, closed-loop Cannabis supply pilot.

On the call, management flagged seasonal softness in Canadian provincial board purchases in the fourth quarter and noted that international sales outside Israel can be uneven because of export permit and shipment timing. The release also lists Israeli anti-dumping inquiries into Canadian medical Cannabis imports among its risks.

Rounding out, the quarter reads like a company growing in three directions with a large cash cushion behind it. The distance between adjusted EBITDA and net income deserves attention. Operating income improved, yet last year’s profit got a lift from currency gains that didn’t repeat. Margins now owe a good share to export sales without excise taxes, so the mix of Canada, Israel and Germany will shape results from here. HCN will monitor the CanAdelaar integration, the outcome of the Dutch Wietexperiment and Canadian ordering trends in Q4 2026.